BunkerHill BMD

by BunkerHill Health  · Based in United States → — Generative AI for clinical reasoning and action.
Endocrinology Radiology Rheumatology
Website
Claim this tool
Is this the maker? Claim the company →

Contact vendor for pricing details.
Regulatory Status Disclosed

Overview

Bunkerhill BMD is an FDA-cleared, post-processing artificial intelligence algorithm developed by Bunkerhill Health to support opportunistic screening for osteoporosis and osteopenia. The software automatically analyzes spinal bone structures from existing, non-contrast abdominal CT scans to estimate average areal bone mineral density (BMD). It operates without requiring additional imaging hardware, calibration phantoms, or patient radiation exposure.

The tool is designed for adults aged 30 years and older. It primarily serves clinical specialties such as radiology, primary care, and women’s health within hospital systems and outpatient imaging centers.

Bunkerhill BMD integrates into clinical workflows via the Carebricks platform. When the algorithm flags a patient with estimated low bone density below a pre-specified threshold, it can automatically trigger downstream care coordination tasks. This includes drafting a confirmatory dual-energy X-ray absorptiometry (DEXA) order for clinician sign-off, preparing patient counseling materials, and initiating scheduling outreach. The tool is intended to support clinical decision-making and retrospective screening, and is not a replacement for diagnostic DEXA scans.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered bone density assessment
  • Utilizes routine non-contrast abdominal CT scans
  • Identifies patients at risk for osteoporosis and osteopenia
  • No additional imaging hardware, calibration phantoms, or radiation exposure required
  • Cleared for adults aged 30 and above
  • Integrates with Bunkerhill's Carebricks platform for end-to-end care navigation
  • Software only medical device (SaMD)
  • Provides a flag for low bone density below a pre-specified threshold

Use Cases

  • Opportunistic screening for osteoporosis/osteopenia
  • Early identification of patients at risk for bone fractures
  • Assisting providers in determining who may benefit from further evaluation, monitoring, or treatment
  • Automated follow-up workflows for patients with low bone density within the Carebricks platform

What Physicians Need to Know

Key Capabilities
Bunkerhill BMD is an FDA-cleared AI algorithm for opportunistic bone density assessment, analyzing spinal bone structures from routine non-contrast abdominal CT scans to identify patients at risk of osteoporosis/osteopenia. It is part of the broader Carebricks platform, which enables health systems to build and deploy AI agents for various clinical and operational workflows, including incidental findings follow-up, prior authorization, and care coordination. The platform also includes FDA-cleared algorithms for various cardiovascular calcifications (coronary artery, aortic valve, mitral annular) and abdominal aortic diameter quantification.
Clinical Utility
The tool enables early detection of osteoporosis/osteopenia from existing CT scans without additional radiation or hardware, addressing underdiagnosis. It streamlines workflows by automating the identification of at-risk patients and coordinating follow-up care (e.g., DEXA scheduling, counseling, patient messaging), thereby improving patient outcomes through earlier intervention and reducing manual clinician workload.
Integration Options
Bunkerhill BMD is integrated within the Carebricks platform, which is designed to integrate AI agents into health system clinical workflows. It processes CT images in DICOM format and can execute actions through third-party services, suggesting compatibility with existing EMRs and PACS. The platform facilitates efficient new customer data integration.
Compliance Status
Bunkerhill BMD has received FDA 510(k) clearance (K2422295) as a Class II Software as a Medical Device (SaMD) for adults aged 30 and above. Bunkerhill Health also holds other FDA clearances for its cardiovascular AI algorithms and has secured CMS reimbursement pathways for AI cardiovascular analysis. The company prioritizes security and compliance with industry standards.
Pricing Model
Specific pricing models for commercial deployment are not explicitly detailed in the provided information. However, the platform and services are offered free of cost for R&D partners for training and validating AI models, with potential for license fees for data contributors. This suggests a licensing or subscription model for commercial use.
User Experience
The tool is designed to work with existing scans, avoiding additional radiation or workflow disruption. The Carebricks platform is described as a 'no-code AI platform,' suggesting ease of use for clinical and operational teams to build and deploy AI agents. It enables seamless collaboration, allowing radiologists to review data and model outputs instantly, reducing feedback cycles.
Implementation Complexity
The 'no-code' nature of the Carebricks platform suggests lower complexity for building and deploying AI agents. The tool works with existing CT scans and requires no additional hardware, simplifying deployment. Efficient data integration capabilities are highlighted, with new customer data integration explored in hours rather than days.
Evidence Base
Bunkerhill BMD was developed within a research consortium of academic medical centers, including Stanford University. Its performance was validated in a retrospective study of 371 CT studies from four diverse sites, achieving 81.0% sensitivity and 78.4% specificity for low bone density detection. The algorithm demonstrated consistent performance across various subgroups and is considered as safe and effective as its predicate device. Bunkerhill Health collaborates with over 20 academic medical centers for AI algorithm development and validation.
Physician Tip

Leverage Bunkerhill BMD for opportunistic screening of osteoporosis/osteopenia in adults aged 30+ from routine abdominal CTs to identify at-risk patients without additional scans or radiation. Integrate AI-flagged findings into existing care pathways to facilitate timely DEXA scheduling and patient counseling. Remember that Bunkerhill BMD is a supportive tool, not a replacement for DXA or other dedicated BMD measurements, and should complement clinical evaluation. Explore the broader Carebricks platform for automating other incidental findings follow-up and care coordination workflows for conditions like cardiovascular calcifications or lung nodules.

Bunkerhill BMD operates within the Carebricks platform, which is designed for seamless integration into health system clinical workflows. It processes standard DICOM CT images and can orchestrate automated actions (e.g., orders, referrals, messages) across various existing systems. The 'no-code' aspect of Carebricks aims to simplify the deployment of AI agents and data integration with current EMRs and PACS.

Details

Category Endocrinology & Metabolic AI, Radiology & Imaging AI
Pricing Contact vendor for pricing details.
DeploymentIntegrated within BunkerHill Health's Carebricks platform, which integrates seamlessly with existing EHRs.
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

BunkerHill BMD received FDA 510(k) clearance (K242295) on April 8, 2025. It is classified as a Class II medical device (bone densitometer, product code KGI) and is a software-only medical device (SaMD) for estimating bone mineral density from previously obtained CT images in adults aged 30 and above.
Integrations
EHR Not specified
Specialties Endocrinology, Radiology, Rheumatology

What the Web Says

BunkerHill BMD is an AI-powered software that assesses bone mineral density from existing non-contrast abdominal CT scans, aiming to opportunistically screen for osteoporosis without additional radiation or specialized hardware. It received FDA 510(k) clearance in April 2025 and is part of Bunkerhill Health's Carebricks platform, which focuses on deploying AI agents to improve clinical, operational, and administrative workflows in healthcare systems. The company recently secured $55 million in Series B funding to scale its platform.

Overall: Positive

Strengths

  • AI-automated assessment of bone mineral density from existing CT scans, avoiding additional radiation exposure.
  • Enhances opportunistic screening for osteoporosis, potentially identifying at-risk patients who might otherwise be missed.
  • Integrates into existing workflows without requiring new imaging hardware or disrupting current processes.
  • Part of a broader 'Carebricks' AI platform that can be used to build and deploy various AI agents for clinical and administrative tasks.
  • Demonstrated success in other areas, such as reducing specialist wait times and improving follow-up care for urgent findings.
  • Trusted by leading health systems like Cleveland Clinic, Intermountain Health, and the University of Texas Medical Branch.

Limitations

  • No specific negative reviews or opinions about BunkerHill BMD were found from physicians, healthcare IT, tech reviewers, Reddit, G2, or Capterra.
  • While individual success stories exist, Bunkerhill has not published data on false positives or broader patient population performance for its AI agents.
  • The downstream financial return-on-investment for opportunistic cardiac screening using AI is not yet clear.
  • General challenges with scaling adoption of new AI technologies in health systems exist.

Based on reviews from: Becker's Hospital Review, Fierce Healthcare, AI News, Axios, G2, Capterra, Reddit, WebMD Doctor, Healthgrades, Indeed.com

Last updated: 2026-07-18

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate BunkerHill BMD

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

AI News
Bunkerhill raises $55M to scale agentic AI across health systems
Bunkerhill Health has secured $55 million in Series B funding to expand its Carebricks agentic AI platform, which enables health systems to build and deploy their own AI agents for clinical, operational, and administrative tasks. The funding round was led by Khosla Ventures and saw continued participation from Sequoia Capital, Felicis, Optum Ventures, and Y Combinator.
2026-07
HIT Consultant
Bunkerhill Health Secures $55M to Expand Carebricks Agentic AI Platform for Health Systems
Bunkerhill Health has closed a $55 million Series B funding round, led by Khosla Ventures, to scale its Carebricks agentic AI platform. The platform allows health systems to create and deploy AI agents across various domains, with existing deployments at institutions like the University of Texas Medical Branch (UTMB), Cleveland Clinic, and Intermountain Health.
2026-07
Diagnostic Imaging
FDA Clears AI-Powered Bone Mineral Density Assessment from Abdominal CT Scans
The FDA has granted 510(k) clearance for Bunkerhill BMD software, an AI-enabled tool that provides automated bone mineral density (BMD) assessments from non-contrast abdominal CT scans. This software, cleared for adults 30 and older, allows for opportunistic screening for osteoporosis without additional imaging hardware or radiation.
2025-04
HLTH
Bunkerhill Health Secures CMS Reimbursement and FDA Clearance for AI Cardiovascular CT Analysis
Bunkerhill Health has achieved two significant regulatory milestones: a national reimbursement pathway from CMS for algorithmic analysis of coronary artery calcium (CAC) and aortic valve calcium (AVC), and FDA clearance for new AI algorithms (Bunkerhill Contrast CAC and Bunkerhill Contrast AVC) to analyze calcium in contrast-enhanced chest CT scans.
2026-04
Applied Radiology
Bunkerhill Health Secures FDA Clearance for AI Tool to Detect Mitral Annular Calcification on Routine CT Scans
Bunkerhill Health received FDA clearance for Bunkerhill MAC, an AI algorithm designed to detect and quantify mitral annular calcification (MAC) on routine, non-gated CT scans. This marks the first FDA authorization for an AI model to identify MAC, a significant marker of cardiovascular risk.
2025-10
Bunkerhill Health (Press Release)
Bunkerhill Health and UTMB Health Advance Clinician-Led AI Innovation at Enterprise Scale
UTMB Health has implemented over 15 live Carebricks workflows, with dozens more in development, showcasing clinician-led agentic AI innovation at an enterprise scale. These AI-driven workflows have led to earlier identification of high-risk patients and improved care velocity.
2026-01
Bunkerhill Health (Press Release)
Bunkerhill Health and Cleerly Announce Strategic Partnership to Advance Noninvasive Cardiovascular Care
Bunkerhill Health and Cleerly have formed a strategic partnership to enhance noninvasive cardiovascular care by expanding access to their FDA-cleared technologies for coronary artery disease detection and risk assessment. The collaboration aims to help health systems identify at-risk patients earlier and provide comprehensive care.
2025-03
Bunkerhill Health (Press Release)
Bunkerhill Health Secures the First FDA Clearance Enabling Automated Aortic Valve Calcification Quantification on Non-Cardiac Chest CT
Bunkerhill Health has received FDA clearance for its AI solution that enables automated aortic valve calcification quantification on non-cardiac chest CT scans. This expands Bunkerhill's health-system-wide solutions for early cardiovascular disease detection.
2025-01

Videos

Product demos, reviews, and walkthroughs for BunkerHill BMD.

View all on YouTube

Frequently Asked Questions

Bunkerhill BMD is an AI-powered algorithm that analyzes existing non-contrast abdominal CT scans, originally acquired for other clinical purposes, to opportunistically assess bone density. It flags patients aged 30 and above who may be at risk for low bone density, assisting providers in identifying those who could benefit from further evaluation or treatment.
Bunkerhill BMD has received FDA 510(k) clearance, indicating its safety and effectiveness as a medical device. As a healthcare AI solution, it operates within the Bunkerhill Health platform, which is designed to integrate clinical AI models into standard workflows, implying adherence to data privacy regulations like HIPAA.
The gold standard for bone density diagnosis remains Dual-energy X-ray Absorptiometry (DXA). Physicians also rely on manual review of imaging and clinical risk factors, but Bunkerhill BMD offers an opportunistic screening method using existing CT scans without additional radiation or dedicated appointments.
While specific pricing details are not explicitly stated, Bunkerhill Health has a business model that involves working with researchers and institutions. Institutions providing de-identified data for AI development and training may be able to leverage these solutions for free in perpetuity, suggesting a potential partnership or subscription-based model for others.
Bunkerhill BMD is intended as an opportunistic screening tool and is not meant to replace DXA or other dedicated bone mineral density measurements. It is cleared for use in adults 30 years and older and analyzes spinal bone structures from non-contrast abdominal CT scans.
In its pivotal testing, the Bunkerhill BMD algorithm achieved a sensitivity of 81.0% and a specificity of 78.4% for detecting low bone density. It also demonstrated a Pearson correlation coefficient of 0.791 and an AUROC of 0.883, further supporting its robustness and reliability.
By leveraging routine CT scans, Bunkerhill BMD enables early detection of osteoporosis and osteopenia in patients who might otherwise go undiagnosed, without requiring additional scans or radiation exposure. This opportunistic screening can lead to timely interventions, potentially reducing the risk of serious fractures and improving preventative care.

Related Tools

SureMediks ProView
SureMediks (Rasimo Systems, LLC)
Clinical Decision Support & Reference
SureMediks is an AI-powered clinical decision support and metabolic health platform that automates care workflows for specialists, providing AI-generated patient summaries, automated chart review, and real-time biometric alerts.
SigXA
SigXA
Documentation & Scribing
SigXA is an AI medical scribe and ambient assistant that transforms patient encounters into structured clinical documentation, specifically tuned for endocrinology teams to manage hormonal and metabolic conditions with protocol-driven longitudinal monitoring.
Paid, free trial
Nirmitee.io Diabetes Care Intelligence
Nirmitee.io
Endocrinology & Metabolic AI
Nirmitee.io Diabetes Care Intelligence is an AI-powered platform that integrates CGM data, analyzes 14-day CGM patterns, and correlates them with insulin doses, meal timing, and activity to generate specific dosing recommendations for personalized diabetes management.
Wellma for Practitioners
Wellma
Clinical Decision Support & Reference
Wellma for Practitioners is an AI co-pilot that extends care plans between sessions, providing real-time client insights, structured follow-up, and pre-session briefs for metabolic health conditions.
Virta Health
Virta Health
Endocrinology & Metabolic AI
Virta Health offers a virtual health program focused on reversing Type 2 diabetes, prediabetes, and obesity through a nutrition-first approach, continuous remote care, and personalized coaching.
Hybrid
PNOĒ
PNOĒ
Endocrinology & Metabolic AI
PNOĒ is a science-backed cardiometabolic analyzer that performs comprehensive breath-based assessments to measure 23 biomarkers, including VO₂ max, resting metabolic rate (RMR), fat burn efficiency, and biological age. It delivers a 360° snapshot of an individual's physiology by analyzing how oxygen flows through the lungs, heart, and cells. The insights generated are used to personalize nutrition, exercise, and longevity plans.
Varies

See all Endocrinology & Metabolic AI tools →

More from Bunkerhill Health

Bunkerhill Abdominal Aortic Quantification (AAQ)
BunkerHill Health
Cardiology AI
Bunkerhill Abdominal Aortic Quantification (AAQ) is the first FDA-cleared AI to automate abdominal aortic diameter quantification on contrast and non-contrast CT scans, enabling early aneurysm detection and streamlined follow-up within the Carebricks platform.
Contact for pricing
Bunkerhill AVC
BunkerHill Health
Cardiology AI
Bunkerhill Health provides a generative AI platform, Carebricks, for clinical reasoning and action, integrating with EHRs to automate workflows and improve patient outcomes. Its FDA-cleared algorithm, Bunkerhill AVC, specifically aids in the early detection and quantification of aortic valve calcification from chest CTs.
Contact for pricing
Bunkerhill ECG-EF
BunkerHill Health
Cardiology AI
Bunkerhill ECG-EF is an FDA-cleared artificial intelligence algorithm by BunkerHill Health that detects reduced left ventricular ejection fraction (LVEF ≤ 40%) from routine 12-lead electrocardiograms (ECGs), aiding in the early identification of patients at risk for heart failure.
Contact for pricing
Bunkerhill MAC
Bunkerhill Health
Cardiology AI
Bunkerhill MAC is an FDA-cleared AI algorithm by Bunkerhill Health that detects and quantifies mitral annular calcification (MAC) on routine CT scans, aiding early cardiovascular risk identification and care coordination within the Carebricks platform.
Contact for pricing

View company profile →

Suggest an Edit → | Last Verified: 2026-04-17 | First Added: 2026-04-17
AI Tool Finder
AI-powered search. Results may not be comprehensive.